Sage News

Jan 1, 1970

Sage Healthcare and Roth Capital Partners Announce European Healthcare Collaboration

Jan 1, 1970

Sage Advises PolyPid on Exclusive U.S. and Canadian Commercial Partnership with Azurity Pharmaceuticals for D-PLEX100

Jan 1, 1970

Respien Appoints Sage to Lead Global Partnering Process for HI-164, a Phase 3-Ready COPD Therapy

Jan 1, 1970

Sage Advises Hatchtech on Pelthos Therapeutics Acquisition of Xeglyze® (abametapir) Topical Treatment for Head Lice

Jan 1, 1970

Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults

Jan 1, 1970

Serpin Pharma Partners with Dogwood Therapeutics to Develop and Commercialize SP16 as a Treatment for Cancer-Related Pain

Jan 1, 1970

Sage Group Advises Fabre-Kramer Pharma on Partnering Deal with Aytu Biopharma for EXXUA(TM), a Newly Approved and Innovative Treatment for Major Depressive Disorder

Jan 1, 1970

Sage New Client: Notogen's Groundbreaking Regenerative Therapy for Degenerative Disc Disease

Jan 1, 1970

PolyPid Announces Successful Completion of Enrollment in Phase 3 SHIELD II Trial of D-PLEX₁₀₀ for the Prevention of Abdominal Colorectal Surgical Site Infections

Jan 1, 1970

Opportunity to License XMVA09, A Phase I First-in-class Intravitreal AAV Therapy Expressing Anti-VEGF and ANG2 Bispecific Antibody

Jan 1, 1970

Opportunity to License SP16, A Novel Treatment For Acute Kidney Injury (AKI)

Jan 1, 1970

Opportunity to Partner Novel VHH Multi-Specific Antibodies Targeted at Solid and Hematologic Tumors

Jan 1, 1970

Sage Healthcare and Roth Capital Partners Announce European Healthcare Collaboration

Jan 1, 1970

Sage Advises PolyPid on Exclusive U.S. and Canadian Commercial Partnership with Azurity Pharmaceuticals for D-PLEX100

Jan 1, 1970

Respien Appoints Sage to Lead Global Partnering Process for HI-164, a Phase 3-Ready COPD Therapy

Jan 1, 1970

Sage Advises Hatchtech on Pelthos Therapeutics Acquisition of Xeglyze® (abametapir) Topical Treatment for Head Lice

Jan 1, 1970

Sage Healthcare and Roth Capital Partners Announce European Healthcare Collaboration

Jan 1, 1970

Sage Advises PolyPid on Exclusive U.S. and Canadian Commercial Partnership with Azurity Pharmaceuticals for D-PLEX100

Jan 1, 1970

Respien Appoints Sage to Lead Global Partnering Process for HI-164, a Phase 3-Ready COPD Therapy

Jan 1, 1970

Sage Advises Hatchtech on Pelthos Therapeutics Acquisition of Xeglyze® (abametapir) Topical Treatment for Head Lice

Jan 1, 1970

Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults

Jan 1, 1970

Serpin Pharma Partners with Dogwood Therapeutics to Develop and Commercialize SP16 as a Treatment for Cancer-Related Pain

Join the sage mailing list

pages

Home

About

Home

News

Sage Roth Collaboration

Single Point

Services

FAQs

News

Contact

Site by Reson8

Join the sage mailing list

pages

Home

About

Home

News

Sage Roth Collaboration

Single Point

Services

FAQs

News

Contact

Site by Reson8

Join the sage mailing list

pages

Home

About

Home

News

Sage Roth Collaboration

Single Point

Services

FAQs

News

Contact

Site by Reson8